TIDMGSK
RNS Number : 9116Q
GlaxoSmithKline PLC
02 March 2021
GlaxoSmithKline plc (the ' Company ')
Vesting of Deferred Annual Bonus Plan Deferred Bonus Awards and
Sale of Ordinary Shares and American Depository Shares
This notification sets out the vesting details for Persons
Discharging Managerial Responsibilities ('PDMRs') of Deferred Bonus
Awards over Ordinary Shares and American Depositary Shares ('ADSs')
made in 2018 under the GlaxoSmithKline 2017 Deferred Annual Bonus
Plan ('DABP') and subsequent sale of Ordinary Shares and ADSs to
meet tax liabilities. In accordance with the shareholder approved
2017 Remuneration Policy and the DABP rules, the awards were
comprised of a mandatory bonus deferral only. The three-year
restricted period for the Deferred Bonus Awards commenced on 1
March 2018 and ended on 1 March 2021. Dividends accrued on the
Awards during the restricted period.
The awards were granted in 2018 as restricted awards over ADSs
for US participants and as nil-cost options over Ordinary Shares
for all other participants.
The closing prices of Ordinary Shares and of ADSs of
GlaxoSmithKline plc on 1 March 2021 were GBP12.0060 and $33.73.
Transaction notification
1. Details of PDMR/person closely associated with them
('PCA')
==== ==============================================================================================
a) Name Ms E Walmsley
==== ======================================== ====================================================
b) Position/status Chief Executive Officer
==== ======================================== ====================================================
c) Initial notification/ Initial notification
amendment
==== ======================================== ====================================================
2. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
==== ==============================================================================================
a) Name GlaxoSmithKline plc
==== ======================================== ====================================================
b) LEI 5493000HZTVUYLO1D793
==== ======================================== ====================================================
3. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transaction(s)
has been conducted
==== ==============================================================================================
a) Description of Ordinary shares of 25 pence each ('Ordinary
the financial Shares')
instrument
ISIN: GB0009252882
==== ======================================== ====================================================
b) Nature of the The vesting of an award in the form of
transaction a nil-cost option over Ordinary Shares
granted in 2018 under the Company's 2017
Deferred Annual Bonus Plan and the subsequent
exercise of the nil-cost option.
==== ======================================== ====================================================
c) Price(s) and Price(s) Volume(s)
volume(s)
==== ======================================== ======================= ========================
GBP0.00 68,716
===================================================================== ========================
d) Aggregated information N/A (single transaction)
====
Aggregated volume
Price
================================================================== ===============================
e) Date of the transaction 2021-03-01
==== ======================================== ====================================================
f) Place of the N/A
transaction
==== ======================================== ====================================================
1. Details of PDMR/person closely associated with them
('PCA')
==== =========================================================================================
a) Name Ms E Walmsley
==== ====================================== =================================================
b) Position/status Chief Executive Officer
==== ====================================== =================================================
c) Initial notification/ Initial notification
amendment
==== ====================================== =================================================
2. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
==== =========================================================================================
a) Name GlaxoSmithKline plc
==== ====================================== =================================================
b) LEI 5493000HZTVUYLO1D793
==== ====================================== =================================================
3. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transaction(s)
has been conducted
==== =========================================================================================
a) Description of Ordinary shares of 25 pence each ('Ordinary
the financial Shares')
instrument
ISIN: GB0009252882
==== ====================================== =================================================
b) Nature of the The sale of Ordinary Shares to meet tax
transaction liabilities on the exercise of a nil-cost
option award granted in 2018 under the
Company's 2017 Deferred Annual Bonus Plan.
==== ====================================== =================================================
c) Price(s) and Price(s) Volume(s)
volume(s)
==== ====================================== ========================= ===================
GBP12.1070 32,346
===================================================================== ===================
d) Aggregated information N/A (single transaction)
====
Aggregated volume
Price
================================================================== ==========================
e) Date of the transaction 2021-03-01
==== ====================================== =================================================
f) Place of the N/A
transaction
==== ====================================== =================================================
1. Details of PDMR/person closely associated with them
('PCA')
==== ==============================================================================================
a) Name Mr R Connor
==== ======================================== ====================================================
b) Position/status President, Global Vaccines
==== ======================================== ====================================================
c) Initial notification/ Initial notification
amendment
==== ======================================== ====================================================
2. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
==== ==============================================================================================
a) Name GlaxoSmithKline plc
==== ======================================== ====================================================
b) LEI 5493000HZTVUYLO1D793
==== ======================================== ====================================================
3. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transaction(s)
has been conducted
==== ==============================================================================================
a) Description of Ordinary shares of 25 pence each ('Ordinary
the financial Shares')
instrument
ISIN: GB0009252882
==== ======================================== ====================================================
b) Nature of the The vesting of an award in the form of
transaction a nil-cost option over Ordinary Shares
granted in 2018 under the Company's 2017
Deferred Annual Bonus Plan and the subsequent
exercise of the nil-cost option.
==== ======================================== ====================================================
c) Price(s) and Price(s) Volume(s)
volume(s)
==== ======================================== ======================= ========================
GBP0.00 14,551
===================================================================== ========================
d) Aggregated information N/A (single transaction)
====
Aggregated volume
Price
================================================================== ===============================
e) Date of the transaction 2021-03-01
==== ======================================== ====================================================
f) Place of the N/A
transaction
==== ======================================== ====================================================
1. Details of PDMR/person closely associated with them
('PCA')
==== =========================================================================================
a) Name Mr R Connor
==== ====================================== =================================================
b) Position/status President, Global Vaccines
==== ====================================== =================================================
c) Initial notification/ Initial notification
amendment
==== ====================================== =================================================
2. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
==== =========================================================================================
a) Name GlaxoSmithKline plc
==== ====================================== =================================================
b) LEI 5493000HZTVUYLO1D793
==== ====================================== =================================================
3. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transaction(s)
has been conducted
==== =========================================================================================
a) Description of Ordinary shares of 25 pence each ('Ordinary
the financial Shares')
instrument
ISIN: GB0009252882
==== ====================================== =================================================
b) Nature of the The sale of Ordinary Shares to meet tax
transaction liabilities on the exercise of a nil-cost
option award granted in 2018 under the
Company's 2017 Deferred Annual Bonus Plan.
==== ====================================== =================================================
c) Price(s) and Price(s) Volume(s)
volume(s)
==== ====================================== ========================= ===================
GBP12.1113 6,857
===================================================================== ===================
d) Aggregated information N/A (single transaction)
====
Aggregated volume
Price
================================================================== ==========================
e) Date of the transaction 2021-03-01
==== ====================================== =================================================
f) Place of the N/A
transaction
==== ====================================== =================================================
1. Details of PDMR/person closely associated with them
('PCA')
==== ==============================================================================================
a) Name Mr N Hirons
==== ======================================== ====================================================
b) Position/status SVP, Global Ethics and Compliance
==== ======================================== ====================================================
c) Initial notification/ Initial notification
amendment
==== ======================================== ====================================================
2. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
==== ==============================================================================================
a) Name GlaxoSmithKline plc
==== ======================================== ====================================================
b) LEI 5493000HZTVUYLO1D793
==== ======================================== ====================================================
3. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transaction(s)
has been conducted
==== ==============================================================================================
a) Description of Ordinary shares of 25 pence each ('Ordinary
the financial Shares')
instrument
ISIN: GB0009252882
==== ======================================== ====================================================
b) Nature of the The vesting of an award in the form of
transaction a nil-cost option over Ordinary Shares
granted in 2018 under the Company's 2017
Deferred Annual Bonus Plan and the subsequent
exercise of the nil-cost option.
==== ======================================== ====================================================
c) Price(s) and Price(s) Volume(s)
volume(s)
==== ======================================== ======================= ========================
GBP0.00 7,630
===================================================================== ========================
d) Aggregated information N/A (single transaction)
====
Aggregated volume
Price
================================================================== ===============================
e) Date of the transaction 2021-03-01
==== ======================================== ====================================================
f) Place of the N/A
transaction
==== ======================================== ====================================================
1. Details of PDMR/person closely associated with them
('PCA')
==== =========================================================================================
a) Name Mr N Hirons
==== ====================================== =================================================
b) Position/status SVP, Global Ethics and Compliance
==== ====================================== =================================================
c) Initial notification/ Initial notification
amendment
==== ====================================== =================================================
2. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
==== =========================================================================================
a) Name GlaxoSmithKline plc
==== ====================================== =================================================
b) LEI 5493000HZTVUYLO1D793
==== ====================================== =================================================
3. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transaction(s)
has been conducted
==== =========================================================================================
a) Description of Ordinary shares of 25 pence each ('Ordinary
the financial Shares')
instrument
ISIN: GB0009252882
==== ====================================== =================================================
b) Nature of the The sale of Ordinary Shares to meet tax
transaction liabilities on the exercise of a nil-cost
option award granted in 2018 under the
Company's 2017 Deferred Annual Bonus Plan.
==== ====================================== =================================================
c) Price(s) and Price(s) Volume(s)
volume(s)
==== ====================================== ========================= ===================
GBP12.1132 3,599
===================================================================== ===================
d) Aggregated information N/A (single transaction)
====
Aggregated volume
Price
================================================================== ==========================
e) Date of the transaction 2021-03-01
==== ====================================== =================================================
f) Place of the N/A
transaction
==== ====================================== =================================================
1. Details of PDMR/person closely associated with them
('PCA')
==== ========================================================================================
a) Name Mr B McNamara
==== ======================================== ==============================================
b) Position/status CEO, GSK Consumer Healthcare
==== ======================================== ==============================================
c) Initial notification/ Initial notification
amendment
==== ======================================== ==============================================
2. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
==== ========================================================================================
a) Name GlaxoSmithKline plc
==== ======================================== ==============================================
b) LEI 5493000HZTVUYLO1D793
==== ======================================== ==============================================
3. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transaction(s)
has been conducted
==== ========================================================================================
a) Description of American Depositary Shares ('ADSs')
the financial
instrument ISIN: US37733W1053
==== ======================================== ==============================================
b) Nature of the The vesting of an award granted in 2018
transaction under the Company's 2017 Deferred Annual
Bonus Plan.
==== ======================================== ==============================================
c) Price(s) and Price(s) Volume(s)
volume(s)
==== ======================================== =================== ======================
$0.00 7,346
=================== ======================
d) Aggregated information N/A (single transaction)
====
Aggregated volume
Price
========================================= ==================================================
e) Date of the transaction 2021-03-01
==== ======================================== ==============================================
f) Place of the N/A
transaction
==== ======================================== ==============================================
1. Details of PDMR/person closely associated with them
('PCA')
==== ==========================================================================================
a) Name Mr B McNamara
==== ======================================== ================================================
b) Position/status CEO, GSK Consumer Healthcare
==== ======================================== ================================================
c) Initial notification/ Initial notification
amendment
==== ======================================== ================================================
2. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
==== ==========================================================================================
a) Name GlaxoSmithKline plc
==== ======================================== ================================================
b) LEI 5493000HZTVUYLO1D793
==== ======================================== ================================================
3. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transaction(s)
has been conducted
==== ==========================================================================================
a) Description of American Depositary Shares ('ADSs')
the financial
instrument ISIN: US37733W1053
==== ======================================== ================================================
b) Nature of the The sale of ADSs' to meet tax liabilities
transaction on the vesting of an award granted in 2018
under the Company's 2017 Deferred Annual
Bonus Plan.
==== ======================================== ================================================
c) Price(s) and Price(s) Volume(s)
volume(s)
==== ======================================== ==================== =======================
$33.7970 3,756
==================== =======================
d) Aggregated information N/A (single transaction)
====
Aggregated volume
Price
========================================= ====================================================
e) Date of the transaction 2021-03-01
==== ======================================== ================================================
f) Place of the N/A
transaction
==== ======================================== ================================================
1. Details of PDMR/person closely associated with them
('PCA')
==== ==============================================================================================
a) Name Mr L Miels
==== ======================================== ====================================================
b) Position/status President, Global Pharmaceuticals
==== ======================================== ====================================================
c) Initial notification/ Initial notification
amendment
==== ======================================== ====================================================
2. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
==== ==============================================================================================
a) Name GlaxoSmithKline plc
==== ======================================== ====================================================
b) LEI 5493000HZTVUYLO1D793
==== ======================================== ====================================================
3. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transaction(s)
has been conducted
==== ==============================================================================================
a) Description of Ordinary shares of 25 pence each ('Ordinary
the financial Shares')
instrument
ISIN: GB0009252882
==== ======================================== ====================================================
b) Nature of the The vesting of an award in the form of
transaction a nil-cost option over Ordinary Shares
granted in 2018 under the Company's 2017
Deferred Annual Bonus Plan and the subsequent
exercise of the nil-cost option.
==== ======================================== ====================================================
c) Price(s) and Price(s) Volume(s)
volume(s)
==== ======================================== ======================= ========================
GBP0.00 13,820
===================================================================== ========================
d) Aggregated information N/A (single transaction)
====
Aggregated volume
Price
================================================================== ===============================
e) Date of the transaction 2021-03-01
==== ======================================== ====================================================
f) Place of the N/A
transaction
==== ======================================== ====================================================
1. Details of PDMR/person closely associated with them
('PCA')
==== =========================================================================================
a) Name Mr L Miels
==== ====================================== =================================================
b) Position/status President, Global Pharmaceuticals
==== ====================================== =================================================
c) Initial notification/ Initial notification
amendment
==== ====================================== =================================================
2. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
==== =========================================================================================
a) Name GlaxoSmithKline plc
==== ====================================== =================================================
b) LEI 5493000HZTVUYLO1D793
==== ====================================== =================================================
3. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transaction(s)
has been conducted
==== =========================================================================================
a) Description of Ordinary shares of 25 pence each ('Ordinary
the financial Shares')
instrument
ISIN: GB0009252882
==== ====================================== =================================================
b) Nature of the The sale of Ordinary Shares to meet tax
transaction liabilities on the exercise of a nil-cost
option award granted in 2018 under the
Company's 2017 Deferred Annual Bonus Plan.
==== ====================================== =================================================
c) Price(s) and Price(s) Volume(s)
volume(s)
==== ====================================== ========================= ===================
GBP12.0992 6,501
===================================================================== ===================
d) Aggregated information N/A (single transaction)
====
Aggregated volume
Price
================================================================== ==========================
e) Date of the transaction 2021-03-01
==== ====================================== =================================================
f) Place of the N/A
transaction
==== ====================================== =================================================
1. Details of PDMR/person closely associated with them
('PCA')
==== ==============================================================================================
a) Name Mr D Redfern
==== ======================================== ====================================================
b) Position/status Chief Strategy Officer
==== ======================================== ====================================================
c) Initial notification/ Initial notification
amendment
==== ======================================== ====================================================
2. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
==== ==============================================================================================
a) Name GlaxoSmithKline plc
==== ======================================== ====================================================
b) LEI 5493000HZTVUYLO1D793
==== ======================================== ====================================================
3. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transaction(s)
has been conducted
==== ==============================================================================================
a) Description of Ordinary shares of 25 pence each ('Ordinary
the financial Shares')
instrument
ISIN: GB0009252882
==== ======================================== ====================================================
b) Nature of the The vesting of an award in the form of
transaction a nil-cost option over Ordinary Shares
granted in 2018 under the Company's 2017
Deferred Annual Bonus Plan and the subsequent
exercise of the nil-cost option.
==== ======================================== ====================================================
c) Price(s) and Price(s) Volume(s)
volume(s)
==== ======================================== ======================= ========================
GBP0.00 14,126
===================================================================== ========================
d) Aggregated information N/A (single transaction)
====
Aggregated volume
Price
================================================================== ===============================
e) Date of the transaction 2021-03-01
==== ======================================== ====================================================
f) Place of the N/A
transaction
==== ======================================== ====================================================
1. Details of PDMR/person closely associated with them
('PCA')
==== =========================================================================================
a) Name Mr D Redfern
==== ====================================== =================================================
b) Position/status Chief Strategy Officer
==== ====================================== =================================================
c) Initial notification/ Initial notification
amendment
==== ====================================== =================================================
2. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
==== =========================================================================================
a) Name GlaxoSmithKline plc
==== ====================================== =================================================
b) LEI 5493000HZTVUYLO1D793
==== ====================================== =================================================
3. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transaction(s)
has been conducted
==== =========================================================================================
a) Description of Ordinary shares of 25 pence each ('Ordinary
the financial Shares')
instrument
ISIN: GB0009252882
==== ====================================== =================================================
b) Nature of the The sale of Ordinary Shares to meet tax
transaction liabilities on the exercise of a nil-cost
option award granted in 2018 under the
Company's 2017 Deferred Annual Bonus Plan.
==== ====================================== =================================================
c) Price(s) and Price(s) Volume(s)
volume(s)
==== ====================================== ========================= ===================
GBP12.1093 6,656
===================================================================== ===================
d) Aggregated information N/A (single transaction)
====
Aggregated volume
Price
================================================================== ==========================
e) Date of the transaction 2021-03-01
==== ====================================== =================================================
f) Place of the N/A
transaction
==== ====================================== =================================================
1. Details of PDMR/person closely associated with them
('PCA')
==== ========================================================================================
a) Name Ms K Terrell
==== ======================================== ==============================================
b) Position/status Chief Digital & Technology Officer
==== ======================================== ==============================================
c) Initial notification/ Initial notification
amendment
==== ======================================== ==============================================
2. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
==== ========================================================================================
a) Name GlaxoSmithKline plc
==== ======================================== ==============================================
b) LEI 5493000HZTVUYLO1D793
==== ======================================== ==============================================
3. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transaction(s)
has been conducted
==== ========================================================================================
a) Description of American Depositary Shares ('ADSs')
the financial
instrument ISIN: US37733W1053
==== ======================================== ==============================================
b) Nature of the The vesting of an award granted in 2018
transaction under the Company's 2017 Deferred Annual
Bonus Plan.
==== ======================================== ==============================================
c) Price(s) and Price(s) Volume(s)
volume(s)
==== ======================================== =================== ======================
$0.00 2,480
=================== ======================
d) Aggregated information N/A (single transaction)
====
Aggregated volume
Price
========================================= ==================================================
e) Date of the transaction 2021-03-01
==== ======================================== ==============================================
f) Place of the N/A
transaction
==== ======================================== ==============================================
1. Details of PDMR/person closely associated with them
('PCA')
==== ==========================================================================================
a) Name Ms K Terrell
==== ======================================== ================================================
b) Position/status Chief Digital & Technology Officer
==== ======================================== ================================================
c) Initial notification/ Initial notification
amendment
==== ======================================== ================================================
2. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
==== ==========================================================================================
a) Name GlaxoSmithKline plc
==== ======================================== ================================================
b) LEI 5493000HZTVUYLO1D793
==== ======================================== ================================================
3. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transaction(s)
has been conducted
==== ==========================================================================================
a) Description of American Depositary Shares ('ADSs')
the financial
instrument ISIN: US37733W1053
==== ======================================== ================================================
b) Nature of the The sale of ADSs' to meet tax liabilities
transaction on the vesting of an award granted in 2018
under the Company's 2017 Deferred Annual
Bonus Plan.
==== ======================================== ================================================
c) Price(s) and Price(s) Volume(s)
volume(s)
==== ======================================== ==================== =======================
$33.7970 976
==================== =======================
d) Aggregated information N/A (single transaction)
====
Aggregated volume
Price
========================================= ====================================================
e) Date of the transaction 2021-03-01
==== ======================================== ================================================
f) Place of the N/A
transaction
==== ======================================== ================================================
1. Details of PDMR/person closely associated with them
('PCA')
==== ==============================================================================================
a) Name Mr P Thomson
==== ======================================== ====================================================
b) Position/status President, Global Affairs
==== ======================================== ====================================================
c) Initial notification/ Initial notification
amendment
==== ======================================== ====================================================
2. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
==== ==============================================================================================
a) Name GlaxoSmithKline plc
==== ======================================== ====================================================
b) LEI 5493000HZTVUYLO1D793
==== ======================================== ====================================================
3. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transaction(s)
has been conducted
==== ==============================================================================================
a) Description of Ordinary shares of 25 pence each ('Ordinary
the financial Shares')
instrument
ISIN: GB0009252882
==== ======================================== ====================================================
b) Nature of the The vesting of an award in the form of
transaction a nil-cost option over Ordinary Shares
granted in 2018 under the Company's 2017
Deferred Annual Bonus Plan and the subsequent
exercise of the nil-cost option.
==== ======================================== ====================================================
c) Price(s) and Price(s) Volume(s)
volume(s)
==== ======================================== ======================= ========================
GBP0.00 9,555
===================================================================== ========================
d) Aggregated information N/A (single transaction)
====
Aggregated volume
Price
================================================================== ===============================
e) Date of the transaction 2021-03-01
==== ======================================== ====================================================
f) Place of the N/A
transaction
==== ======================================== ====================================================
1. Details of PDMR/person closely associated with them
('PCA')
==== =========================================================================================
a) Name Mr P Thomson
==== ====================================== =================================================
b) Position/status President, Global Affairs
==== ====================================== =================================================
c) Initial notification/ Initial notification
amendment
==== ====================================== =================================================
2. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
==== =========================================================================================
a) Name GlaxoSmithKline plc
==== ====================================== =================================================
b) LEI 5493000HZTVUYLO1D793
==== ====================================== =================================================
3. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transaction(s)
has been conducted
==== =========================================================================================
a) Description of Ordinary shares of 25 pence each ('Ordinary
the financial Shares')
instrument
ISIN: GB0009252882
==== ====================================== =================================================
b) Nature of the The sale of Ordinary Shares to meet tax
transaction liabilities on the exercise of a nil-cost
option award granted in 2018 under the
Company's 2017 Deferred Annual Bonus Plan.
==== ====================================== =================================================
c) Price(s) and Price(s) Volume(s)
volume(s)
==== ====================================== ========================= ===================
GBP12.1030 4,507
===================================================================== ===================
d) Aggregated information N/A (single transaction)
====
Aggregated volume
Price
================================================================== ==========================
e) Date of the transaction 2021-03-01
==== ====================================== =================================================
f) Place of the N/A
transaction
==== ====================================== =================================================
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
DSHELLFBFXLZBBQ
(END) Dow Jones Newswires
March 02, 2021 10:48 ET (15:48 GMT)
Gsk (LSE:GSK)
Gráfica de Acción Histórica
De Feb 2024 a Mar 2024
Gsk (LSE:GSK)
Gráfica de Acción Histórica
De Mar 2023 a Mar 2024